

antiviral and associated therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
ivermectin	11 studies ¹	0.94 [0.77 ; 1.15], 3 RCTs, I2=0% inconclusive result	1.07 [0.98 ; 1.17], 2 RCTs, I2=0% inconclusive result	0.93 [0.54 ; 1.59], 4 RCTs, I2=0% inconclusive result	0.92 [0.77 ; 1.09], 2 RCTs, I2=0% inconclusive result
chloroquine and derivatives	8 studies ²	0.51 [0.07 ; 3.68], 1 RCT, I2=0% inconclusive result	1.36 [0.87 ; 2.11], 1 RCT, I2=0% inconclusive result	1.32 [0.44 ; 3.93], 5 RCTs, I2=0% inconclusive result	0.93 [0.62 ; 1.40], 2 RCTs, I2=0% inconclusive result
azithromycin	4 studies ³	-	1.08 [0.95 ; 1.23], 1 RCT, I2=0% inconclusive result	1.65 [0.03 ; 83.12], 1 RCT, I2=0% inconclusive result	715.00 [12.94 ; 39513.71], 1 study, I2=0% certainty unassessable
fluvoxamine	4 studies ⁴	0.72 [0.45 ; 1.16], 3 RCTs, I2=61% demonstrated inconclusive result	-	0.80 [0.43 ; 1.50], 1 RCT, I2=0% inconclusive result	0.67 [0.42 ; 1.06], 1 RCT, I2=0% inconclusive result
hydroxychloroquine plus macrolides	2 studies ⁵	-	-	-	0.91 [0.54 ; 1.51], 2 RCTs, I2=0% inconclusive result
molnupiravir	2 studies ⁶	-	-	0.10 [0.01 ; 0.92], 2 RCTs, I2=0% high degree of certainty	14.50 [1.70 ; 123.69], 1 RCT, I2=0% certainty unassessable
lopinavir/ritonavir	1 study ⁷	-	-	0.26 [0.01 ; 5.88], 1 RCT, I2=0% inconclusive result	0.92 [0.82 ; 1.03], 1 RCT, I2=0% inconclusive result
nirmatrelvir / ritonavir (Paxlovid)	1 study ⁸	-	-	0.04 [0.00 ; 0.70], 1 RCT, I2=0% certainty unassessable	-
nitazoxanide	1 study ⁹	-	-	-	-
remdesivir	1 study ¹⁰	-	-	1.01 [0.02 ; 51.30], 1 RCT, I2=0% inconclusive result	-

Continued on next page

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
sofosbuvir and daclatasvir	1 study ¹¹	-	-	-	-
zinc	1 study ¹²	-	-	-	-

Notes

¹ACTIV-6 (ivermectine), 2023 (NCT04885530); ACTIV 6 ivermectin, 2022 (NCT04885530); COVID-OUT (ivermectin), 2022 (NCT04510194); TOGETHER (ivermectine), 2022 (NCT04727424); Lopez-Medina, 2021 (NCT04405843); Chaccour, 2020 (NCT04390022); Chowdhury A, 2020 (NCT04434144); IVERCORCOVID19 (Vallejos), 2020 (NCT04529525); Podder, 2020 (); Chahla, 2021 (NCT04784481); Espitia-Hernandez, 2020 ()

²COPE – Coalition V, 2022 (NCT04466540); PATCH Cohort 1 (Amaravadi), 2021 (NCT04329923); Reis (Hydroxychloroquine) (TOGETHER), 2021 (NCT04403100); BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 (NCT04304053); COMIHY, 2020 (NCT04340544); COVID-PEP Severity (Skipper), 2020 (NCT04308668); Q-PROTECT -HCQ alone, 2020 (NCT04349592); Agusti, 2020 ()

³ACTION, 2021 (NCT04332107); Hinks (ATOMIC2), 2021 (NCT04381962); PRINCIPLE, 2021 (ISRCTN86534580); Espitia-Hernandez, 2020 ()

⁴ACTIV-6, 2022 (NCT04885530); COVID-OUT (fluvoxamine), 2022 (NCT04510194); TOGETHER, 2021 (NCT04727424); Lenze (STOP COVID 1), 2020 (NCT04342663)

⁵Rodrigues, 2021 (); Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 (NCT04349592)

⁶Fischer (all doses), 2021 (NCT04405570); MOVE-OUT, 2021 (NCT04575597)

⁷Reis (Lopinavir-ritonavir) (TOGETHER), 2021 (NCT04403100)

⁸EPIC-HR, 2021 (NCT04960202)

⁹RM08-3008 (Rossignol), 2021 (NCT04486313)

¹⁰PINETREE (GS-US-540-9012), 2021 (NCT04501952)

¹¹Roosbeh, 2020 (IRCT20200403046926N1)

¹²Thomas (zinc only), 2021 (NCT04342728)